MARKET

GILD

GILD

Gilead Sciences Inc
NASDAQ
138.36
+0.22
+0.16%
After Hours: 138.00 -0.36 -0.26% 19:53 08/14 EDT
OPEN
136.81
PREV CLOSE
138.14
HIGH
138.43
LOW
135.91
VOLUME
3.41M
TURNOVER
--
52 WEEK HIGH
155.38
52 WEEK LOW
106.44
MARKET CAP
171.56B
P/E (TTM)
-52.1110
1D
5D
1M
3M
1Y
5Y
1D
Gilead Sciences (GILD) Could Be 8% Overvalued As AI Deal And Q2 Results Lift Shares
Simply Wall St · 19h ago
Gilead Sciences (GILD) Gets a Hold from Barclays
TipRanks · 1d ago
Pharma companies sour on Swiss drug applications amid Trump’s MFN policy
Seeking Alpha · 1d ago
Your prescription drugs shouldn’t cost more than your mortgage. Inside the broken math that got us here.
MarketWatch · 1d ago
Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD
NASDAQ · 1d ago
Moderna Inc. Stock Rises 5.1%, Outperforms Peers
Dow Jones · 2d ago
Gilead Sciences (GILD) Starts AI Biomarker Research Partnership For Oncology
Simply Wall St · 2d ago
Legend Biotech downgraded at Oppenheimer on CEO exit, competition
Seeking Alpha · 2d ago
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.

Webull offers Gilead Sciences, Inc stock information, including NASDAQ: GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.